InnoCare has dosed the first patient in the P-Ib clinical evaluation of ICP-189 + fumetinib for treating advanced or metastatic non-small cell lung cancer (NSCLC) across China
The company collaborated with ArriVent BioPharma in Jul 2023 to expedite the development of ICP-189 in combination with fumetinib (EGFR kinase inhibitor) for treating advanced or metastatic NSCLC
ICP-189 (oral) is a SHP2 allosteric inhibitor demonstrating effectiveness when used as a monotx. and favorable PK characteristics as well as safety were observed in its dose-escalation trial with 120 mg without any DLTs
Ref: InnoCare | Image: Innocare
Related News:- InnoCare Receives IND Approval from NMPA to Initiate P-I Study of ICP-189 + Furmonertinib in NSCLC Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
